|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
| 05-14 | Biophytis unveils design for obesity study | CF |
| 05-14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Biophytis S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was EUR 17.03 million compared to EUR 24.22 million a year ago. Basic loss per share from continuing operations was EUR 12 compared to EUR 56 a year ago.
Diluted loss per share from continuing operations was EUR 12 compared to EUR 56 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -58.33% | 2.49M | |
| +7.84% | 113B | |
| +10.37% | 106B | |
| +0.41% | 22.27B | |
| -12.02% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.92% | 17.24B | |
| +7.12% | 14.29B | |
| +36.44% | 12.52B |
BIOPHYTIS S.A. 
